EVOTEC SE

Evotec SE and Sandoz AG have announced a non-binding agreement for the potential sale of Evotec’s Toulouse biologics facility to Sandoz for approximately $300 million.

Evotec SE receives $2.5 million grant from the Gates Foundation to develop new tuberculosis treatment regimens, but its stock price drops amid concerns over its financial stability.

Evotec SE has received a $2.5 million grant from the Bill & Melinda Gates Foundation to develop next-generation tuberculosis treatments, despite facing financial challenges and a recent stock price decline.